

Claim Version with markings showing changes made

1. (Presently amended) A method of blocking or reducing physiological reaction in a mammal to the interaction of IgE antibodies present in said mammal upon contact with the corresponding antigen, by the administration to said mammal of a therapeutically effective amount of a neurotoxin (CnT) derived wherein (CnT) is any biological substance having essentially the same biological effect within cells as the wild types of Clostridia neurotoxins from Clostridia sp wherein said Clostridia are selected from the group consisting of C. botulinum, C. butyricum, and C. beratti .
5
2. (Original) The method of claim 1 wherein the mammal is a member of H. sapiens.
10
3. (Presently amended) The method of Claim 2 wherein the ~~neurotoxin is derived from a~~ the species of Clostridia is selected from the group consisting of C. botulinum, C. butyricum, C. beratti and C. Tetani .
15
4. (Presently amended) The method of claim 3 wherein the serotypes of C. botulinum ~~are neurotoxins (BoNT), derived from C. botulinum, are derived from~~ serotypes A, B, C1, D, E, F and G
20
5. (Cancelled).
25
6. (Original) The method of claim 1 wherein CnT is administered by contact with absorbant pledgets having CnT absorbed thereon.
30
7. (Original) The method of claim 1 wherein CnT is administered by contact with biodegradable carrier containing CnT .
35
8. (Original) The method of claim 1 wherein CnT is administered by injection.
9. (Presently amended) The method of claim 1 wherein CnT is administered by myringotomy ~~into tympanic membranes.~~
10. (Original) The method of claim 1 wherein CnT is administered by injection into the pterygoplatine space through the palate.
11. (Original) The method of claim 7 wherein CnT is administered to pass through the nasal wall to the sphenopalatine ganglia .

12. (Presently amended) The method of claim 1 wherein CnT is administered by inhalation of an aqueous mist containing ~~same~~ said CnT.
- 5 13. (Original) The method of claim 1 wherein CnT is administered by injection to the nasal mucosa.
14. (Presently amended) The method of claim 1 wherein CnT is administered by application of a suppository containing ~~same~~ said CnT.
- 10 15. (Presently amended) The method of claim 1 wherein the physiological reaction is manifested by a condition or symptoms selected from the group consisting of allergic rhinitis, infectious rhinitis, serous otitis media, sinusitis, pulmonary disease, nasal congestion, food allergies, allergic dermatitis, ~~and~~ sneezing, coughing, itching and excess mucous secretion related to allergic reactions.
- 15 16. (Original) The method of claim 15 wherein the pulmonary disease is selected from the group consisting of bronchitis, emphysema and hypereactive asthma.
17. (Original) The method of claim 1 wherein CnT is administered by contact with absorbant pledgets having CnT absorbed thereon.
- 20 18. (Original) The method of claim 1 wherein the amount of CnT administered per administration is between about 0.1 and about 1000 units per administration.
- 25 19. (Original) The method of claim 1 wherein the amount of CnT administered per administration is between about 1 and about 100 units per administration.
20. (Original) The method of claim 1 wherein the amount of CnT administered per administration is between about 1 and about 20 units per administration.
- 30 21. (Cancelled)
22. (Cancelled)
- 35 23. (Cancelled)
24. (Cancelled)

25. (New) The method of claim 1 wherein CnT is administered by injection across the cricothyroid membrane